Dishman Carbogen Amcis Ltd's Q4FY25 Quarter Results
- 22 May 2025
Result Summary
- Dishman Carbogen Amcis Ltd reported a 3.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.8%.
- Its expenses for the quarter were up by 6.8% QoQ and 6.1% YoY.
- The net profit decreased 1610.2% QoQ and decreased 1.1% YoY.
- The earnings per share (EPS) of Dishman Carbogen Amcis Ltd declined at 4.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 661.87 | 687.97 | 625.31 | -3.8% | 5.8% |
Total Expenses | 707.98 | 662.96 | 667.29 | 6.8% | 6.1% |
Profit Before Tax | -49.20 | 27.05 | -87.60 | -281.9% | -43.8% |
Tax | 20.72 | 22.42 | -16.88 | -7.6% | -222.7% |
Profit After Tax | -69.92 | 4.63 | -70.72 | -1610.2% | -1.1% |
Earnings Per Share | -4.50 | 0.30 | -4.50 | -1600.0% | 0.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dishman Carbogen Amcis Ltd is a company engaged in the pharmaceutical industry, offering a range of products and services that support the pharmaceutical and biopharmaceutical sectors. This includes contract research and manufacturing services. The company is known for its expertise in high-potency pharmaceutical ingredients and provides integrated development and manufacturing services to the global pharmaceutical market. As of the latest data, the company has not reported any significant major developments that affect its operational or financial landscape. The absence of additional information about recent developments or strategic initiatives suggests that the company continues to operate within its established business framework.
Revenue
For the quarter ending in Q4FY25, Dishman Carbogen Amcis Ltd reported total income of ₹661.87 crores, compared to ₹687.97 crores in Q3FY25 and ₹625.31 crores in Q4FY24. This reflects a quarter-over-quarter (QoQ) decrease of 3.8% and a year-over-year (YoY) increase of 5.8%. The decline in total income on a QoQ basis suggests a decrease in revenue-generating activities compared to the previous quarter, while the YoY growth indicates an overall improvement in revenue compared to the same quarter in the previous fiscal year.
Profitability
In Q4FY25, Dishman Carbogen Amcis Ltd's profit before tax stood at a negative ₹49.20 crores, down from ₹27.05 crores in Q3FY25, and up from a negative ₹87.60 crores in Q4FY24. The QoQ change in profit before tax is a decrease of 281.9%, while the YoY change shows an improvement of 43.8%. The tax expense for Q4FY25 was ₹20.72 crores, compared to ₹22.42 crores in Q3FY25 and a negative tax of ₹16.88 crores in Q4FY24, leading to a QoQ decrease of 7.6% and a significant YoY change of 222.7%. The profit after tax for Q4FY25 was negative ₹69.92 crores, compared to a positive ₹4.63 crores in Q3FY25 and a negative ₹70.72 crores in Q4FY24. The QoQ change is a decrease of 1610.2%, while the YoY change is a slight improvement of 1.1%. Earnings per share remained unchanged YoY at negative ₹4.50, with a significant QoQ decrease from ₹0.30.
Operating Metrics
Total expenses for Q4FY25 increased to ₹707.98 crores from ₹662.96 crores in Q3FY25 and ₹667.29 crores in Q4FY24. This marks a QoQ increase of 6.8% and a YoY increase of 6.1%. The increase in expenses QoQ and YoY indicates heightened operational costs during the quarter. The company did not report any specific operating metrics such as production volumes or capacity utilization rates, which could provide further insights into operational efficiency. The financial data presented highlights the company's focus on managing its cost structure while facing challenges in maintaining profitability.
